has reported global net revenues of nearly $14bn for the second quarter (Q2) of 2021, reflecting a 33.9% surge on a reported basis compared to $10.42bn in the same period last year.
Net revenue grew 19.3% on a comparable operational basis in Q2 2021.
For the quarter ended 30 June 2021, the GAAP diluted earnings per share (EPS) slightly declined to $0.42 from $0.46 in Q2 last year.
Adjusted diluted EPS, excluding specified items, rose to $3.11 in the second quarter of 2021, as against $2.34 in the prior-year quarter.
Global net revenues from the immunology portfolio for the Q2 of this year totalled $6.12bn, witnessing a growth of 15.1% on a reported basis and 13.8% on a comparable operational basis.
In the US region, Humira (adalimumab)聽generated net revenues of $4.26bn, a 7.1% increase on a reported basis in Q2 2021.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFurthermore, Humira’s international net revenues decreased 6% on a reported basis to $811m, owing to biosimilar competition.
During the quarter, the hematologic oncology and neuroscience portfolios generated $1.81bn and $1.5bn in global net revenues, up 14.1% and 98.8%, respectively, on a reported basis.
Aesthetics portfolio鈥檚 global net revenues grew more than 100% on a reported basis to $1.43bn.
The company added that overall net revenues of eye care and women鈥檚 health businesses increased by more than 100% and 29.9%, respectively, while other major products saw a 19.9% rise on a reported basis.
AbbVie chairman and CEO Richard Gonzalez said: 鈥淎bbVie delivered another strong quarter and our business continues to perform extremely well across the portfolio, with AbbVie鈥檚 new immunology assets contributing more than $1bn of combined sales in the quarter.
鈥淭he Allergan integration also continues to track exceptionally well, with both the neuroscience and aesthetics portfolios delivering double-digit sequential growth.鈥�
AbbVie has updated its GAAP diluted EPS guidance for the full year 2021 from $7.27 to $7.47 to $6.04 to $6.14.
Furthermore, the adjusted diluted EPS for the full-year 2021 was increased to $12.52 t o$12.62 from $12.37 to $12.57.
Last month, the company聽expanded its partnership with Calico Life Sciences聽to discover, develop and commercialise novel treatments for age-related diseases such as neurodegeneration and cancer.
